Premium
Decreased tetranectin in multiple myeloma
Author(s) -
Nielsen Henrik,
Clemmensen Inge,
Nielsen Hans J.,
Drivsholm Aage
Publication year - 1990
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830330213
Subject(s) - multiple myeloma , hemoglobin , medicine , catabolism , albumin , cancer research , pathology , immunology , endocrinology , biology , metabolism
Tetranectin, a recently described human protein widely distributed in the body and with possible importance for cell growth and differentiation, has previously been observed to be decreased in patients with solid malignant tumors. In patients with multiple myeloma, either untreated or previously treated, serum levels were found to be significantly reduced. A negligible interindividual variation was observed. Levels of serum tetranectin were not correlated with serum albumin, hemoglobin, or M‐component. Low levels of tetranectin may be related to the growth and spread of malignant cells or reflect a general catabolic state of chronic disease.